Kodiak Sciences Inc. Notes to Consolidated Financial Statements (in thousands, except share and per share data) 128 The following potentially dilutive securities, presented on an as-converted to common stock basis, were excluded from the computation of diluted net loss per share attributable to common stockholders for the period presented because including them would have been antidilutive: Year Ended December 31, 2018 Year Ended December 31, 2017 Year Ended December 31, 2016 Exercise of options outstanding ................................................................ 5,135,267 1,204,414 1,263,757 Unvested restricted stock awards.............................................................. 50,450 291,633 549,351 Unvested early exercised common stock options ..................................... — 2,887 19,336 Conversion of redeemable convertible preferred stock ............................ — 12,385,154 12,385,154 Conversion of convertible notes outstanding............................................ — 2,153,781 — Exercise of preferred stock warrants outstanding..................................... — 500,000 — Total .......................................................................................................... 5,185,717 16,537,869 14,217,598 15. 401(k) Plan In 2011, the Company adopted a 401(k) retirement and savings plan covering all employees. The 401(k) plan allows employees to make pre- and post-tax contributions up to the maximum allowable amount set by the Internal Revenue Service. The Company does not make matching contributions to the 401(k) plan on behalf of participants. 16. Related Party Transactions Baker Bros. Advisors LP, which holds more than 5% of the Company’s stock, purchased $6.6 million aggregate principal amount of 2018 convertible notes and $3.0 million aggregate principal amount of 2017 convertible notes and warrants to purchase an aggregate of 150,000 shares of the Company’s Series B redeemable convertible preferred stock (see Note 6 and 12). The Dustin Moskovitz Trust DTD 12/27/05, which holds more than 5% of the Company’s stock, purchased $3.0 million aggregate principal amount of 2018 convertible notes and $5.0 million aggregate principal amount of 2017 convertible notes and warrants to purchase an aggregate of 250,000 shares of the Company’s Series B redeemable convertible preferred stock (see Note 6 and 12). 17. Selected Quarterly Financial Data (unaudited) The following table provides the selected quarterly financial information for the years 2018 and 2017 (in thousands, except per share data): Three Months Ended March 31, 2018 June 30, 2018 September 30, 2018 December 31, 2018 Loss from operations .............................................. $ (5,547) $ (5,090) $ (6,380) $ (9,357) Net loss and comprehensive loss............................ $ (8,920) $ (7,409) $ (10,452) $ (14,662) Net loss per share attributable to common stockholders, basic and diluted............................ $ (1.16) $ (0.96) $ (1.33) $ (0.40) Three Months Ended March 31, 2017 June 30, 2017 September 30, 2017 December 31, 2017 Loss from operations .............................................. $ (5,043) $ (6,742) $ (3,979) $ (9,757) Net loss and comprehensive loss............................ $ (5,041) $ (6,742) $ (4,583) $ (11,570) Net loss per share attributable to common stockholders, basic and diluted............................ $ (0.68) $ (0.90) $ (0.61) $ (1.52)